Cargando…

Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression

[Image: see text] The use of computational tools to identify biological targets of natural products with anticancer properties and unknown modes of action is gaining momentum. We employed self-organizing maps to deconvolute the phenotypic effects of piperlongumine (PL) and establish a link to modula...

Descripción completa

Detalles Bibliográficos
Autores principales: Conde, João, Pumroy, Ruth A., Baker, Charlotte, Rodrigues, Tiago, Guerreiro, Ana, Sousa, Bárbara B., Marques, Marta C., de Almeida, Bernardo P., Lee, Sohyon, Leites, Elvira P., Picard, Daniel, Samanta, Amrita, Vaz, Sandra H., Sieglitz, Florian, Langini, Maike, Remke, Marc, Roque, Rafael, Weiss, Tobias, Weller, Michael, Liu, Yuhang, Han, Seungil, Corzana, Francisco, Morais, Vanessa A., Faria, Cláudia C., Carvalho, Tânia, Filippakopoulos, Panagis, Snijder, Berend, Barbosa-Morais, Nuno L., Moiseenkova-Bell, Vera Y., Bernardes, Gonçalo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161495/
https://www.ncbi.nlm.nih.gov/pubmed/34079902
http://dx.doi.org/10.1021/acscentsci.1c00070
_version_ 1783700524109922304
author Conde, João
Pumroy, Ruth A.
Baker, Charlotte
Rodrigues, Tiago
Guerreiro, Ana
Sousa, Bárbara B.
Marques, Marta C.
de Almeida, Bernardo P.
Lee, Sohyon
Leites, Elvira P.
Picard, Daniel
Samanta, Amrita
Vaz, Sandra H.
Sieglitz, Florian
Langini, Maike
Remke, Marc
Roque, Rafael
Weiss, Tobias
Weller, Michael
Liu, Yuhang
Han, Seungil
Corzana, Francisco
Morais, Vanessa A.
Faria, Cláudia C.
Carvalho, Tânia
Filippakopoulos, Panagis
Snijder, Berend
Barbosa-Morais, Nuno L.
Moiseenkova-Bell, Vera Y.
Bernardes, Gonçalo J. L.
author_facet Conde, João
Pumroy, Ruth A.
Baker, Charlotte
Rodrigues, Tiago
Guerreiro, Ana
Sousa, Bárbara B.
Marques, Marta C.
de Almeida, Bernardo P.
Lee, Sohyon
Leites, Elvira P.
Picard, Daniel
Samanta, Amrita
Vaz, Sandra H.
Sieglitz, Florian
Langini, Maike
Remke, Marc
Roque, Rafael
Weiss, Tobias
Weller, Michael
Liu, Yuhang
Han, Seungil
Corzana, Francisco
Morais, Vanessa A.
Faria, Cláudia C.
Carvalho, Tânia
Filippakopoulos, Panagis
Snijder, Berend
Barbosa-Morais, Nuno L.
Moiseenkova-Bell, Vera Y.
Bernardes, Gonçalo J. L.
author_sort Conde, João
collection PubMed
description [Image: see text] The use of computational tools to identify biological targets of natural products with anticancer properties and unknown modes of action is gaining momentum. We employed self-organizing maps to deconvolute the phenotypic effects of piperlongumine (PL) and establish a link to modulation of the human transient receptor potential vanilloid 2 (hTRPV2) channel. The structure of the PL-bound full-length rat TRPV2 channel was determined by cryo-EM. PL binds to a transient allosteric pocket responsible for a new mode of anticancer activity against glioblastoma (GBM) in which hTRPV2 is overexpressed. Calcium imaging experiments revealed the importance of Arg539 and Thr522 residues on the antagonistic effect of PL and calcium influx modulation of the TRPV2 channel. Downregulation of hTRPV2 reduces sensitivity to PL and decreases ROS production. Analysis of GBM patient samples associates hTRPV2 overexpression with tumor grade, disease progression, and poor prognosis. Extensive tumor abrogation and long term survival was achieved in two murine models of orthotopic GBM by formulating PL in an implantable scaffold/hydrogel for sustained local therapy. Furthermore, in primary tumor samples derived from GBM patients, we observed a selective reduction of malignant cells in response to PL ex vivo. Our results establish a broadly applicable strategy, leveraging data-motivated research hypotheses for the discovery of novel means tackling cancer.
format Online
Article
Text
id pubmed-8161495
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-81614952021-06-01 Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression Conde, João Pumroy, Ruth A. Baker, Charlotte Rodrigues, Tiago Guerreiro, Ana Sousa, Bárbara B. Marques, Marta C. de Almeida, Bernardo P. Lee, Sohyon Leites, Elvira P. Picard, Daniel Samanta, Amrita Vaz, Sandra H. Sieglitz, Florian Langini, Maike Remke, Marc Roque, Rafael Weiss, Tobias Weller, Michael Liu, Yuhang Han, Seungil Corzana, Francisco Morais, Vanessa A. Faria, Cláudia C. Carvalho, Tânia Filippakopoulos, Panagis Snijder, Berend Barbosa-Morais, Nuno L. Moiseenkova-Bell, Vera Y. Bernardes, Gonçalo J. L. ACS Cent Sci [Image: see text] The use of computational tools to identify biological targets of natural products with anticancer properties and unknown modes of action is gaining momentum. We employed self-organizing maps to deconvolute the phenotypic effects of piperlongumine (PL) and establish a link to modulation of the human transient receptor potential vanilloid 2 (hTRPV2) channel. The structure of the PL-bound full-length rat TRPV2 channel was determined by cryo-EM. PL binds to a transient allosteric pocket responsible for a new mode of anticancer activity against glioblastoma (GBM) in which hTRPV2 is overexpressed. Calcium imaging experiments revealed the importance of Arg539 and Thr522 residues on the antagonistic effect of PL and calcium influx modulation of the TRPV2 channel. Downregulation of hTRPV2 reduces sensitivity to PL and decreases ROS production. Analysis of GBM patient samples associates hTRPV2 overexpression with tumor grade, disease progression, and poor prognosis. Extensive tumor abrogation and long term survival was achieved in two murine models of orthotopic GBM by formulating PL in an implantable scaffold/hydrogel for sustained local therapy. Furthermore, in primary tumor samples derived from GBM patients, we observed a selective reduction of malignant cells in response to PL ex vivo. Our results establish a broadly applicable strategy, leveraging data-motivated research hypotheses for the discovery of novel means tackling cancer. American Chemical Society 2021-04-14 2021-05-26 /pmc/articles/PMC8161495/ /pubmed/34079902 http://dx.doi.org/10.1021/acscentsci.1c00070 Text en © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Conde, João
Pumroy, Ruth A.
Baker, Charlotte
Rodrigues, Tiago
Guerreiro, Ana
Sousa, Bárbara B.
Marques, Marta C.
de Almeida, Bernardo P.
Lee, Sohyon
Leites, Elvira P.
Picard, Daniel
Samanta, Amrita
Vaz, Sandra H.
Sieglitz, Florian
Langini, Maike
Remke, Marc
Roque, Rafael
Weiss, Tobias
Weller, Michael
Liu, Yuhang
Han, Seungil
Corzana, Francisco
Morais, Vanessa A.
Faria, Cláudia C.
Carvalho, Tânia
Filippakopoulos, Panagis
Snijder, Berend
Barbosa-Morais, Nuno L.
Moiseenkova-Bell, Vera Y.
Bernardes, Gonçalo J. L.
Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
title Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
title_full Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
title_fullStr Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
title_full_unstemmed Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
title_short Allosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression
title_sort allosteric antagonist modulation of trpv2 by piperlongumine impairs glioblastoma progression
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161495/
https://www.ncbi.nlm.nih.gov/pubmed/34079902
http://dx.doi.org/10.1021/acscentsci.1c00070
work_keys_str_mv AT condejoao allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT pumroyrutha allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT bakercharlotte allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT rodriguestiago allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT guerreiroana allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT sousabarbarab allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT marquesmartac allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT dealmeidabernardop allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT leesohyon allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT leiteselvirap allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT picarddaniel allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT samantaamrita allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT vazsandrah allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT sieglitzflorian allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT langinimaike allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT remkemarc allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT roquerafael allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT weisstobias allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT wellermichael allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT liuyuhang allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT hanseungil allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT corzanafrancisco allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT moraisvanessaa allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT fariaclaudiac allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT carvalhotania allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT filippakopoulospanagis allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT snijderberend allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT barbosamoraisnunol allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT moiseenkovabellveray allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression
AT bernardesgoncalojl allostericantagonistmodulationoftrpv2bypiperlongumineimpairsglioblastomaprogression